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Abstract 
Rhabdomyosarcoma (RMS) is a sarcoma more frequent in children, which arises from 
the disruption of regulatory mechanisms that leads to the myogenic phenotype. RMS 
cells have low levels of muscle differentiation markers. Ezh2 is a histone 
methyltransferase part of the PRC2 complex and at the early stage of myogenesis it 
silences muscle specific genes (even MyoD target genes) consenting the proper timing 
of muscle specific gene expression. During skeletal differentiation in myoblasts, Ezh2 
displaces from myogenic regulatory regions and MyoD dependent transcription is co-
activated by the complex Cdk9/CycT2. The cyclin dependent kinase 9 and one of its 
cyclin partners, cyclin T2, are MyoD interacting proteins that together form a complex 
whose main activity is phosphorylating the carboxyl terminal domain of RNApolII on 
muscle specific promoters allowing stabilization of the nascent transcripts. 
Surprisingly, its kinase activity is abrogated in RMS. Our results show that Ezh2 
depletion in a human rhabdomyosarcoma cell line causes a partial reactivation of the 
myogenic program, more in particular a reactivation of MyoD target genes such as 
myosin heavy chain (MyH) and myogenin (Myog) and, in addition these data correlate 
with an increase in the elongating RnapolII at Myog and Myh promoters. Further 
analyses demonstrated the restoration of Cdk9 occupancy at Myog and Myh 
promoters in RD-Ezh2-KD cells providing evidence for an inhibitory effect of EZh2 on 







Elena Vittoria Mura “Polycomb protein Ezh2 controls rhabdomyosarcoma formation” 











         Elena Vittoria Mura “Polycomb protein Ezh2 controls rhabdomyosarcoma formation” 
Tesi di dottorato in Scienze Biomolecolari e Biotecnologiche Università degli Studi di Sassari 
 
1.1. Rhabdomyosarcoma: pathology and molecular pathogenesis 
Rhabdomyosarcoma (RMS) is a rare soft tissue sarcoma, more frequent in children, which 
accounts for 3-4% of childhood cancers. It is caused by the disruption of regulatory 
mechanisms that lead to the myogenic phenotype in primitive mesenchymal stem cells. 
The annual incidence of this kind of tumor in children, adolescents, and young adults 
under the age of 20 is 4.3 cases per one million population and two-thirds of the cases are 
diagnosed in children younger than 6 years of age. 5-year overall survival rate is 68,9% 
(Okcu et al., 2011). The etiology of the disease is still unknown, but some familial 
syndromes have been associated with it such as neurofibromatosis, the Li-Fraumeni, 
Beckwith-Wiedemann, and Costello syndromes (Okcu et al., 2011; Xia et al., 2002). RMS 
comprises two histological subtypes, alveolar (aRMS) and embryonal (eRMS), each of 
them with different prognosis and various genetic and molecular alterations. As an 
example, 80% of aRMS harbor a translocation with fuses the 5’ end of PAX3 or PAX7 
(transcription factors that initiate myogenesis in muscle stem cells) with the 3' end of the 
FOXO1A gene. The resulting chimeric protein is a potent transcription factor that 
stimulates myogenesis and resists apoptosis (Jain et al., 2010; Linardic, 2008). The eRMS, 
on which we focused our attention, typically occurs in the head, neck and genitourinary 
sites and is associated with loss of heterozigosity on the short arm of chromosome 11 
(the 11p15.5 region) which codify for various tumor suppressing genes (Loh et al., 1992; 
Koi et al., 1993) imprinted in physiological but not in pathologic conditions. One of them 
is the CDKN1C (p57/KIP2) gene, expressed during development in several tissues, 
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Comparative genomic hybridization (CGH) and fluorescent in situ hybridization studies 
(FISH) have also identified in eRMS gains and losses in other chromosomes. Moreover, 
many studies support alterations of different pathways such as the pRb, the Ras, and the 
p53 pathways (Xia et al., 2002). On the basis of its genetic alterations, in 
rhabdomyosarcoma there is evidence of deregulation in the mechanisms controlling the 
cell cycle. 
Rhabdomyoblasts appear like partially differentiated cells showing nuclear expression, to 
varying degrees, of myogenic nuclear regulatory proteins like myogenin and MyoD (Sebire 
and Malone, 2003), whose immunohistochemical analyses are necessary for the diagnosis 
of the tumor (Dias et al., 1990, 2000; Morgenstern et al., 2008). RMS cells have low levels 
of other late differentiation markers. Cluster analysis and comparison of the expression 
profiles of normal muscle, RMS, and fetal muscle confirmed the high degree of similarity 
between the fetal muscle and RMS transcriptomes. Nevertheless, gene and epigenetic 
alterations could further contribute to maintaining the proliferative state of RMS and 
consequently prevent myogenic differentiation (Schaaf et al., 2005).  
1.2. An overview of skeletal muscle differentiation and correlated critical 
points in rhabdomyosarcoma  
Myoblasts are committed-muscle cell precursors that produce myogenic transcription 
factors. Until growth factors are present in the environment myoblasts proliferate 
without differentiating. When these factors are depleted, the myoblasts stop dividing and 
leave the cell cycle. The consequent step is the alignment of myoblasts together into 
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Several myogenic transcription factors such as MyoD, Myf5, myogenin (Myog), MRFs, 
coordinate together skeletal muscle differentiation. They belong to the family of bHLH 
myogenic transcription factors as they share the basic-helix-loop-helix regulatory motif. 
The basic domain is required for DNA binding of promoter binding sites termed E-boxes 
whereas the HLH domain is required for dimerization.  
Among muscle specific transcription factors, MyoD is a master regulator of the myogenic 
program and upon condition permissive to myogenesis it initiates skeletal muscle 
differentiation. MyoD heterodimerizes with other bHLH proteins, such as the E2A gene 
products E12 and E47, also called E-proteins, to recognize its numerous target genes 
(Lassar et al., 1991; Puri and Sartorelli, 2000). High-throughput ChIP-Seq analysis 
performed in differentiating myoblasts indicate that MyoD binds to several sites 
throughout the genome, although MyoD activity is regulated and MyoD occupancy at 
promoters doesn’t always correlate with transcription (Aziz et al., 2010). MyoD also 
recruits HATs on chromatin such as P300 and PCAF, and after the acetylation of MyoD 
itself and of lysine residues on histones, mediates the recruitment of the complex 
SWI/SNF and other myogenic transcription factors on muscle specific promoters, thereby 
inducing transcription of regulatory and structural muscle speciﬁc genes (Eckner et al., 
1994; Eckner et al., 1996; Puri and Sartorelli, 2000; Iezzi et  al., 2002). 
MRFs instead collaborate with MEF2 transcription factors family to activate muscle gene 
expression (Sartorelli and Caretti, 2005). 
RMS is a suitable model to study pathological myogenesis because cells fail to undergo 
terminal differentiation. The transition from the G1 to the S phase of the cell cycle is 
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major substrates of Cdks are the retinoblastoma tumor suppressor protein pRb and its 
related proteins, p107 and p130 (also named RB family proteins). Ipophosphorylated pRb 
binds the E2F transcription factor on the regulatory regions of its target genes in 
myoblasts repressing transcription from genes involved in DNA synthesis. When Cdks 
phosphorylate pRb, it detaches from its binding sites allowing transition to the S phase of 
the cell cycle (Sidle et al., 1996). 
During terminal myogenesis Cdks activities are downregulated and terminal 
differentiation correlates with cell cycle arrest (Franklin and Xiong, 1996). Cyclin-
dependent kinase inhibitors (CdkIs) induce dephosphorylation of pRb by inhibiting the 
binding of cyclin-dependent kinases CDK4 and CDK6 to cyclin D1, resulting in G1 growth 
arrest (Serrano et al., 1993).  
The RD cell line is a human cell line of embryonal rhabdomyosarcoma whose model is 
currently used to study pathological myogenesis. RD cells maintain elevated levels of 
Cdk4, Cdk6 and their cyclin partners in conditions favoring differentiation compared to 
myoblasts. In fact, in RD cells the concomitant alterations of CdkIs activities preclude to 
attenuate them and fail to arrest the cell cycle (Knudsen et al., 1998).  
1.3. Role of the Cyclin dependent kinase 9 in muscle development 
The Cyclin-Dependent Kinase 9 (Cdk9) is a member of the Cdks family widely expressed at 
high levels in terminally differentiated cells in all human and murine tissues (Bagella et al., 
1998, 2000; Simone et al., 2002). Cdks form heterodimers with their cyclin partners, 
regulating cell cycle progression and transcription. The heterodimer deriving from the 
association of Cdk9 and the cyclin of the T (T1 and T2a or T2b) and K families is the main 
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transcription machinery and RNA polymerase II (polII) on genes regulatory regions, 
displacing negative effectors like the negative transcription elongating factor (N-TEF) and 
allowing the elongation of the nascent RNA. The main role of the Cdk9/CycT complex is to 
phosphorylate the carboxyl terminal domain (CTD) of the RNA PolII (Fig.1) (reviewed from 
Romano and Giordano 2008). 
Cdk9 has two isoforms named Cdk942 and Cdk955 on the basis of their molecular weight. 
Cdk955 differs from Cdk942 in 117 additional amino acid residues at the amino terminus 
region, in frame with the Cdk942 coding sequence (Shore et al., 2003). Although the two 
isoforms are differentially expressed in tissues and particular stimuli can affect the ratio 
Cdk955 to Cdk942 (like in activated macrophages or in hepatocytes in culturing conditions 
(Shore et al., 2005), Cdk955 is very similar to Cdk942 in many respects: ability to associate 
with cyclins, association with 7SK and HEXIM1 (that regulate kinase activity), and kinase 











Fig.1. RNA polymerase II comes under the control of negative elongation factors 
(DSIF and NELF) shortly after initiation. PTEFb (also named CDK9/CyCT) mediates 
a transition into productive elongation by phosphorylating the CTD of the large 
subunit of RNA polymerase II.  
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The CTD of RNApolII is evolutionarily conserved, and in fungi, plants and animals it 
comprises from 25 to 52 tandem copies of the consensus repeat heptad Y1S2P3T4S5P6S7 
(Fig.2) (Corden, 1990). Phosphorylation occurs on Ser2 and Ser5 of the repeats (Dahmus, 
1994; Marshall et al., 1996; Zhou et al., 2001; Sano et al., 2002), and phosphorylation 
state changes as RNAPolII progresses through the transcription cycle (Weeks et al., 1993; 
Dahmus, 1994). This way modification of the CTD by the Cdk9/CycT complex contributes 
to the activation of transcriptional events, and different states of the CTD are 
characteristic of different transcriptional stages. Thus, RNApolII phosphorylated at Ser2 
(Ser2P CTD) and Ser5 (Ser5P CTD) is in the active state and its presence on promoter 







The Cdk9/CycT complex is recruited on its target genes by two different mechanisms: 
gene-specific recruitment through interactions with transactivators and indirect 
recruitment via the interaction between P-TEFb and Brd4. Several transcription factors 
have been reported to bind directly to P-TEFb and recruit the complex on specific 
promoters. P-TEFb was initially identified as the cellular cofactor for transactivator (Tat) 
protein of the human immunodeficiency virus type 1 in human cells (Lin et al., 2002). 
Fig.2. Heptapeptide repeat of RNApolII CTD. Yellow circles indicate Cdk9/CycT 
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Several reports have demonstrated the interaction of Cdk9 and Cyclin T1 with factors 
such as NF-kB, androgen receptor, HIC, aryl hydrocarbon receptor, c-myc, and pRb which 
activate transcription by specific regulatory regions (Grana, X., et al., 1994; Barboric et al., 
2001; Lee et al., 2001; Eberhardy and Farnham 2002; Simone et al., 2002; Kanazawa et al., 
2003; Young et al., 2003; Tian et al., 2003). 
Further studies also suggest an important role of Cdk9 coupled with its cyclin partners in 
skeletal muscle development where Cdk9 exerts its activity in synergy with myogenic 
transcription factors. For example, Cdk9/CycT1 selectively enhances myocyte enhancer 
factor 2 (Mef2c) dependent transcription in murine myoblasts induced to differentiate 
where Cdk9/CycT1 and Mef2c co-occupy the promoters of MEF2c target genes (Nojima M 
et al., 2008) 24h after induction of myogenesis. Similarly, Cdk9 together with cyclin T2a or 
T2b activates MyoD dependent transcription in myoblasts triggered to differentiate and 
the complex Cdk9/CycT2 binds MyoD through its bHLH region (Simone et al., 2002a). 
Overexpression experiments of CDK9 and CycT2 increase the rate of the myogenic 
program while ectopic expression of dominant negative mutants of Cdk9 impairs muscle 
specific expression, such as myosin heavy chain (MyH) and muscle creatine kinase (MKC) 
levels (Simone et al., 2002b). In addition, Cdk9/CycT2 occupies the Myog promoter and 
the enhancer of muscle creatine kinase during muscle differentiation and this event 
correlates with phosphorylation of the CTD of RNapolII (Giacinti et al., 2006). Besides its 
kinase activity, it is important to stress that Cdk9 participates to the formation of a 
multimeric complex on myogenic gene regulatory regions containing MyoD, Mef2, 
histone acetyl transferases (HATs), like p300, PCAF and SWI/SNF besides several enzymes. 




         Elena Vittoria Mura “Polycomb protein Ezh2 controls rhabdomyosarcoma formation” 
Tesi di dottorato in Scienze Biomolecolari e Biotecnologiche Università degli Studi di Sassari 
acetylation of specific lysine residues on histones H3 and H4 and phosphorylation of the 
RNA polymerase II CTD (Fig.3) (Puri and Sartorelli 2000; Giacinti et al., 2006). Significantly, 
cyclin T1 was not detected on the same regions, suggesting a Cyclin T2-depedent Cdk9 







Interestingly, RD cells fail to complete the myogenic program and Cdk9/CycT2 fails to 
phosphorylate MyoD in rhabdomyoblasts triggered to differentiate, despite Cdk9 and 
CycT2 protein levels are comparable with myoblasts and any mutation was detected in 
Cdk9 and CycT2 coding sequences. Enforced expression of MyoD in RD cell increases the 
production of late muscle specific markers but does not reverse the tumorigenic 
phenotype nor completely recapitulates the myogenic program. Moreover, 
overexpression of Cdk9/CycT2 or MyoD cannot rescue the function of the complex, 
suggesting the possible presence of a mechanism inhibiting the complex in 
rhabdomyosarcoma (Simone and Giordano 2007).  
Fig.3. Activation of MyoD dependent-transcription by Cdk9/CycT2. A MyoD-dependent histone 
acetylation is the initial event at the promoter region of genes and it is mediated by HATs. MyoD 
recognizes an E-box site through an interaction with the E-protein. When MyoD recognizes its 
target it recruits and binds a muscle specific transcription factor (TF) and the complex 
Cdk9/CycT2, which phosphorylates the CTD of RnapolII (tail of the red rectangle) activating 
transcription. The blue rectangle represents the E-box sequence on the promoter region of 
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1.4. Role of Ezh2 in muscle development and RMS progression 
During development differentiation programs global rearrangements are required in 
repression and activation of lineage-specific genes. Chromatin based epigenetic 
mechanisms ensure the correct integration of developmental signals at gene regulatory 
regions, allowing correct temporal expression of genes. 
The Polycomb group, (PcG) proteins regulate developmental processes in embryonic stem 
cells (ESCs) leading to a particular cell fate. In human, two PcG multimeric complexes have 
been identified and named Polycomb repressive complex 1 (PRC1) and 2 (PRC2). These 
proteins repress the early differentiation genes to maintain the pluripotency of ESCs at 
the embryonic stage. At the initiation of cell fate commitment, those genes are activated 
while PcG proteins suppress the late differentiation genes for specific cell lineages (Chou 
et al., 2001). 
The enhancer of Zeste homologue 2 (Ezh2) is part of the PRC2 complex. Human Ezh2 took 
its name from the fly homologue E(Z) in Drosophila melanogaster, where the protein was 
first discovered and characterized (Ketel et al., 2005; Cao and Zhang, 2004). Three PcG 
proteins, enhancer of zeste2 (Ezh2), embryonic ectoderm development (Eed), and 
suppressor of zeste 12 homolog (Suz12), comprise the core of PRC2, which mediates 
trimethylation of histone H3 lysine 27 (H3K27me3) (Cao et al., 2002; Czermin et al., 2002; 
Kuzmichev et al., 2002; Muller et al., 2002). Ezh2, a SET domain-containing histone 
methyltransferase (HMTase), is the catalytic subunit of PRC2. Its activity, in concert with 
histone deacetylases (DHACs) and DMTs, stabilizes chromatin and represses transcription 
of many key developmental regulators in embryonic stem cells through H3K27me3 and 
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The precise mechanisms of PRC-mediated gene silencing have not been completely 
understood yet. H3K27me3 PRC2-dependent is the fundamental feature of PcG-mediated 
repression whereas PRC1 is viewed as the direct executor of silencing (Simon and 
Kingston, 2009).  
It has been suggested that the PRC1 can prevent the ATP-dependent nucleosome 
remodeling by the SWI/SNF and RNA polymerase II recruitment (Francis and Kingston, 
2001; Dellino et al., 2004; Wang et al., 2004). Moreover the complex can induce gene 
silencing by chromatin compaction (Francis et al., 2004) and the ubiquitylation of H2A, 
modification associated with gene repression (Wang et al., 2004; Cao et al., 2005). 
Polycomb silencing and DNA methylation have often been considered biochemically 
independent gene silencing systems. However, recent studies show that E  2 and     s 
are ph sicall  and func onall  linked and that E  2 acts upstream of     s to meth late 
and silence target chroma n ( ir  et al., 2006). The mechanism is not yet clear, but a 
hypothesis is that target genes are initially silenced through histone H3-K27 methylation 
by PRC2. PRC2 recruits DNA methyltransferases which methylate CpG DNA of target 
genes, leading to a more permanently or deeply silenced chromatin state (Ohm et al., 
2007; Schlesinger et al., 2007; Widschwendter et al., 2007). 
As well as DNMTs, the PRC2 complex collaborates with other epigenetic silencing 
enzymes. In human cells, PRC2 can associate with histone deacetylases (HDACs) 1 and 2 
providing functional synergy to silencing of target genes. HDACs may deacetylate H3-K27 
or other lysine residues in order to adjust the local histone code for silencing (van Der 
Vlag and Otte, 1999; Muller et al., 2002; Kuzmichev et al., 2002; Cao et al., 2002; Czermin 
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precise mechanisms of this synergy at target genes are not yet clear. HDACs may 
deacetylate H3-K27 to make the ε-amino group available for methylation by PRC2. 
Alternatively, HDACs may deacetylate other histone lysines, such as H3-K9, H3-K14 or H4-
K8, in order to adjust the local histone code for silencing (van Der Vlag and Otte, 1999; 
Muller et al., 2002; Kuzmichev et al., 2002; Cao et al., 2002; Czermin et al., 2002; 
Varambally et al., 2002; Cao and Zhang, 2004). A hypothetic model for PcG-mediated 
silencing is shown in Fig.4. 
Typically, in adult tissues, EZH2 is concentrated in undifferentiated progenitor cell 
populations, such as hematopoietic cells of the pro-B lymphocyte lineage (Su et al., 2003) 
and it is down-regulated in adult differentiated tissues (Varambally et al., 2002; Bracken 
et al., 2003; Kleer et al., 2003). Moreover, in contrast to widespread EZH2 role in early 
mouse development (O’Carroll et al., 2001; Erhardt et al., 2003), post-embryonic EZH2 
expression is limited (Hobert et al., 1996; Laible et al., 1997). 
 Interestingly, EZH2 is overexpressed in a variety of different tumors. EZH2 levels are 
abnormally elevated in cancer tissues versus corresponding normal tissues, with higher 
expression correlates with advanced stages of disease and poor prognosis (for review 
Simon and Lange 2008). 
Indeed, Ezh2 has been linked to aggressive cancers of the prostate (Varambally et al., 
2002), breast (Raaphorst et al., 2003), melanoma and endometrial cancer (Bachmann et 
al., 2006) and its expression is higher in tumor tissues than in normal tissues (Bracken et 
al., 2003). 
It is thereby demonstrated that disruption of EZH2 expression may lead the cell cycle, in 
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transcription factors, and its expression is higher in pRb-deficient tumor (Bracken et al., 
2003). 
The predominant current view is that EZH2 functions in cancer as a transcriptional 
repressor that silences an array of target genes, including tumor suppressor and tissue 
specific differentiation genes. 
Ezh2 implication in tumorigenesis is then strictly correlated with other associated 
chromatin modifying enzymes. For example, ectopic expression of Ezh2 in prostate cells 
induces gene silencing of a speciﬁc cohort of genes and this is strictly dependent on 
histone deacetylase activity (Varambally et al., 2002).  
For what regards muscle differentiation, it has been shown that PRC2 binds and represses 
numerous MyoD target genes in embryonic staminal cells by establishing H3K27 tri-
methylation (Lee et al., 2006). Moreover, although MyoD is expressed in undifferentiated 
skeletal myoblasts, Ezh2 forms a complex with YY1 on promoters and enhancers of the 
muscle-specific genes, thus silencing several MyoD target genes. After the commitment of 
myogenesis, PRC2-binding at MyoD loci is lost, inducing muscle gene expression and 
skeletal muscle differentiation (Caretti et al., 2004). Indeed, accordingly to its role in 
repressing transcription Ezh2 is not detected on myogenic regulatory regions in terminally 
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To ensure proper spatial and temporal expression of muscle-specific genes during skeletal 
differentiation, PcG proteins are overcome by Trithorax group proteins (TrxG), through 
demethylation of H3K27me3 within the promoters of genes and methylation on H3K4, 
Fig.4. Hypothetic model for PcG-mediated gene silencing. A. First Ezh2 silences gene through 
methylation of H3K27. If an acetyl group occupies K27, it is removed by DHACs (that are known 
to interact with Ezh2). HDAC is shown in pink and the dotted line indicates its deacetylase 
activity at K27 before the methyltransferase activity of Ezh2. Ac indicates the acetyl group. B. 
Ezh2 recruits DNMTs, which methylate CpG islands on promoter regions, leading to a more 
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which instead is a transcriptionally permissive mark. Removal of H3K27me3 requires RNA 
Pol II elongation (Seenundun et al., 2010), a process mediated by CTD phosphorylation 
pTEFb-dependent (Ni et al., 2004).  
These data demonstrated that EZH2 plays a key role in skeletal-muscle differentiation, 
specifically in the maintenance of the undifferentiated state of muscle cell precursors and 
suggests that its deregulation may participate at RMS formation and progression by 
muscle specific genes silencing. Moreover these studies could suggest a role of EZH2 in 
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Recent findings confirm the relevance of epigenetic and genetic alterations in the 
progression of cancer. Particular epigenetic patterns are associated with multiple cancer 
types as they frequently occur in tumor suppressor genes promoters. Our study focuses 
on Ezh2, a histone methyltransferase whose disruption has been linked to cancerogenesis 
in a wide variety of tumors. Previous data showed that Ezh2 regulates muscle gene 
expression during myogenesis, ensuring the proper timing of transcription from muscle 
specific promoters. RMS cells show lower levels of skeletal differentiation markers 
compared to myoblasts and have significantly elevated levels of Ezh2, whose 
overexpression has been linked to a large variety of cancers. Interestingly, Cdk9/CycT2 
activity, previously shown to be a crucial coactivator of myogenesis, is abrogated in RMS 
cells although the expression levels of the two subunits of the complex are similar to 
normal myoblasts. The aim of the project is to understand if and how Ezh2 participates to 
rhabdomyosarcoma formation and verify the assumption that it could alter 
transcriptional regulation. To achieve this goal we choose to study in detail whether Ezh2 
depletion changes the activation state of muscle specific promoters. In addition, our goal 
is to clarify if Ezh2 interferes with Cdk9/CycT2 activity, preventing terminal differentiation 
in RMS, in order to try to reverse the tumorigenic phenotype and highlight new 
therapeutic targets for cancer treatment.  
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3.1. Cell culture and differentiation 
The RD cell line was obtained from the American Type Culture Collection (ATCC, Rochville, 
MD, USA). The stable RD-Ezh2-KD cell line had been previously created in our laboratory, 
introducing in the cells an shRNA against Ezh2 by lentiviral vectors. Both cell lines were 
grown at 37C, in a humidiﬁed incubator containing 5% CO2, in  ulbecco’s modiﬁed Eagle’s 
medium (Invitrogen) supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine 
and antibiotics (Growth medium, GM) until reaching confluence. After, that skeletal 
differentiation was induced changing the medium with Differentiation Medium (DM), 
containing  ulbecco’s modiﬁed Eagle’s medium and 2% HS for 96h. Pellets were collected 
each 24h. 
3.2. RT-PCR  
Total RNA was extracted with HIGH PURE RNA ISOLATION KIT (Roche Applied Science, 
Indianapolis, USA) according to the manufacturer’s protocol. 1ug of total R A was retro-
transcribed in 20ul of final volume, containing 10mM dNTPs, DTT 0,1M, random primers 
2ug/ul and MML-  Reverse  ranscriptase (Invitrogen) following the manufacturer’s 
protocol. After reaction double distilled, water was added until reaching a final volume of 
200ul.  
Real time PCR was performed using primers specifically designed for human MyoD, MyH, 
Myog and Gapdh, using 4,5ul of cDNA and 5,5ul of Fast Start Universal SYBR Green 
Master (ROX) (Roche Applied Science, Indianapolis, USA), and 250nM of each primer. The 
primer efficiency was calculated for every target using 10 fold serial dilutions of PCR 
products. 
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Amplification conditions for all the amplicons were 95°C for 10 minutes, followed by 40 
cycles of 95°C for 15s, 60°C for 30s, 72°C for 30s. To ensure specific PCR amplification, 
every real time PCR run was followed by a dissociation phase analysis (denaturation 
curve). 
Accumulation of fluorescent products was monitored using the BIORAD IQ5 instrument. 
Each data point was obtained from three independent experiments. The relative 
expressions were calculated with the ΔΔC  method.  ranscripts levels for glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) were used as a reference and RD and RD-EZH2-KD 
at 0h of differentiation was used as the calibrator point.  
Primer sequences: 
hMyoD forward:  GACGGCATGATGGACTACAGC 
hMyoD reverse:  GGAGATGCGCTCCACGATGC   
hMyH forward:  GGAGGAGGCTGATGAACAAGC 
hMyH reverse:  GGAGGAGGCTGATGAACAAGC 
hMyog forward:  CCTGCTCAGCTCCCTCAACC 
hMyog reverse:  AGGGTCAGCCGTGAGCAGATG 
hGapdh forward:  GAAGGTGAAGGTCGGAGT 
hGapdh reverse:  CATGGGTGGAATCATATTGGA 
3.3. Immunoblotting 
Protein extracts were collected from whole cell lysates after 0h, 24h, 48h, 72h, 96h in DM 
in a non denaturing lysis buffer containing 20 mM Tris HCl pH 8; 137 mM NaCl; 10% 
glycerol, 1% Nonidet P-40; 2 mM EDTA, 20mM NaF and 0,1mM Na3VO4. Protein 
quantification was performed with a Bradford assay, using BSA as a standard. 60ug of 
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total proteins extracts were resolved in 8% and 10% PAA-GELS and transferred to a 
nitrocellulose membrane (Amersham, IL) at 4˚C and at 100  for 1 hour.  he blots were 
blocked for 40’ at room temperature with TBS-T containing 5% non-fat dry milk. 
Antibodies speciﬁc for   o , C C 2, myogenin, MyH (Santa Cruz, CA), Cdk9 (Rockland), 
Ezh2 (Invitrogen), RNA Polymerase II (Santa CRUZ, CA), P-Serine2-CTD, P-Serine5-CTD 
(Bethyl Laboratories Inc., Montgomery, TX) were used to detect protein levels. Anti-70 
kDa heat shock protein (Hsp70) and anti-Gapdh were used to control equal loading of the 
proteins. Anti-rabbit (1:10000), anti-mouse (1:10000) and anti-goat (1:2500) peroxidase 
conjugated antibodies (Pierce) and ECL detection system (PerkinElmer) were used for 
detection.  
3.4. Chromatin Immunoprecipitation 
ChIP was performed with ChIP-IT EXPRESS ENZYMATIC KIT (Active motif, CA, USA) 
according to the manufacturer’s protocol. Cells were grown in 150 x 25mm tissue culture 
dishes in GM to 70-80% confluence and triggered to differentiate for 72h in DM. Cells 
were fixed for 5 minutes with 1% formaldehyde, pelleted and lysated in non denaturing 
lysis buffer, nuclei were isolated and chromatin was prepared according to the 
instructions of the protocol. It was then shared in a digestion buffer containing an 
enzymatic shearing cocktail for 15 minutes and the reaction was stopped with the 
addition of cold 0,5M EDTA. 200ul of chromatin was used to analyze shearing efficiency 
and chromatin was quantified after phenol/chloroform extraction and precipitation. 
ChIP was performed with 50ug of chromatin and anti-Ezh2 (Millipore), anti-RNAPolII, anti-
Ser2CTD, anti-Ser5CTD (Bethyl Laboratories Inc., Montgomery, TX) and anti-CDK9 
(Rockland) antibodies O/  at 4˚C. Rabbit and mouse IgG were used as negative controls. 
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The sheared chromatin samples were subjected to cross-link reversal and treated with 
proteinase K. 
PCR amplifications were performed with primers specifically designed within human 
Myog and MyH promoters. 
Fold enrichments of ChIP were calculated as a ratio of the amplification efficiency of the 
ChIP sample over the IgG’s (rabbit, mouse and goat IgG depending on the antibody used, 
all purchased from Santa Cruz) and each data point represents the medium of three 
independent experiments.  
Real time PCR was performed with primers designed within the promoter regions of 
Myog and MyH promoters, and amplification efficiency was calculated using 10 fold 
dilutions of input DNA qPCR amplified along with the ChIP and IgG samples. Amplification 
conditions were 95°C for 10 minutes, followed by 45 cycles at 95°C for 15s, 58°C for 30s, 
72°C for 30s.  
hMyogenin promoter forward: GAGAGGGGAATGTGTCCTCC 
hMyogenin promoter reverse: CTTCTTTCTCCCGCATGGCC 
hMyh promoter forward: CTCGTCAGAAGCCGATTCTAC 
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4.1. Analyses of transcriptional regulation in rhabdomyosarcoma and 
recovering of muscle gene expression in RD-EZH2-KD differentiating cells 
Previous works revealed a crucial role of Ezh2 in skeletal muscle differentiation as its 
transcriptional and post-transcriptional downregulation is required to allow activation of 
muscle-specific genes (Caretti et al 2004, Juan et al., 2009). The polycomb repressive 
complex 2 (PRC2) represses transcription on myogenic genes regulatory regions through 
the histone methyltransferase activity of Ezh2. Overexpression of this protein in C2C12 
myoblasts impairs differentiation and inhibits skeletal muscle genes expression (Caretti et 
al., 2004). Thus, we supposed that such protein in rhabdomyosarcoma could interfere 
with the normal myogenic transcriptional program and cause defective enrollment of 
transcriptional factors on myogenic regulatory regions. 
We previously generated an Ezh2-KD-RD cell line with a lentiviral vector containing an 
shRNA against Ezh2 (unpublished results). At first we validated the Knockdown by 
performing a Real time PCR for Ezh2 for both RD-WT and RD-EZH2-KD cells. Ezh2 mRNA 
expression levels in the RD-EZH2-KD cell line resulted reduced to 70% compared to the 
RD-WT (Fig.5). We supposed that Ezh2 overexpression in rhabdomyosarcoma could 
blockade the proper activation of genes during myogenesis, preventing cells to complete 
terminal differentiation. Thus, we chose early and late differentiation markers, such as 
Myog and MyH, whose expression has been already related to Ezh2 (Caretti et al., 2004), 
to detect changes in the activation of the transcriptional myogenic program.  
To evaluate the effect of Ezh2 depletion on muscle-specific expression we monitored the 
temporal expression of the myogenic markers in RD-WT and RD-EZH2-KD cells cultured in 
conditions favoring either growth or differentiation. Skeletal muscle differentiation was 
induced replacing growth medium (GM) with differentiation medium (DM) in confluent 
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cells. As Ezh2 controls timing of muscle specific gene expression and its expression is 
differentially regulated during myogenesis the transcripts and protein levels of MyoD, 
Myogenin (early markers of muscle differentiation) and Myh (late marker of muscle 
differentiation) were analyzed at 0, 24, 48, 72, 96h after induction of differentiation with 
Real Time PCR (Fig.6). As previously reported Ezh2 mRNA was robustly represented in RD-
WT differentiating cells while MyoD, Myogenin and Myh transcripts levels were only 
detectable in all the stages analyzed. Conversely, the myogenic markers transcripts levels 
clearly increased in RD-EZH2-KD differentiating cells at every time point analyzed. A 
similar profile was obtained by Western blot analyses in both RD-WT and RD-EZH2-KD 
although to a lesser extent for MyoD (Fig.7). Those data together indicate that Ezh2 
inhibits muscle gene expression in RD-WT differentiating cells. Although a partial 
reactivation of the myogenic program was obtained, we could not observe a complete 
reversion of the tumorigenic phenotype but a significant change was detected in cells 
morphology. In fact RD-EZH2-KD cultured for 72h in DM showed a more lengthened 
phenotype (Fig.8).    
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Fig.6. Expression levels of MyoD, MyoG, MyhC measured by real-time PCR in human 
RD-WT and RD-EZH2-KD at 0h in GM and at 24, 48, 72, 96h in DM. Transcription levels 
were normalized to GAPDH expression and represent the mean of three independent 
experiments ± SD. Fold enrichment was calculated in comparison to RD in GM. 
 
Fig.5. Expression levels of Ezh2 measured by Real Time PCR in 
human RD-WT and RD-EZH2-KD at 48h in DM. Transcription levels 
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Fig.7. Immunoblot of MyoG, MyoD, MyhC, Ezh2 from whole cell extracts of 
human RD-WT and RD-EZH2-KD at 0h in GM and at 0, 24, 48, 72, 96h in DM. 
C2C12 murine myoblasts at 72h in DM were used as a positive control and 
equal loading was performed with an anti Hsp70 antibody.  
 
Fig.8. RD-WT (on the left side) and RD-EZH2-KD (on the right side) cells cultured 
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4.2. Ezh2 occupies Myog and MyH promoters in human RD 
rhabdomyosarcoma cells inhibiting gene expression  
Once established that Ezh2 overexpression in RD-WT impedes transcription, a chromatin 
immmunoprecipitation (ChIP) was performed with an antibody against Ezh2 to evaluate if 
this protein directly mediated the inhibition of muscle gene expression. RD-WT were 
induced to differentiate and chromatin was precipitated from whole cell protein extracts 





Myh promoters (Fig.9). The ChIP analysis showed that Ezh2 strongly occupies Myog and 
Myh promoters in RD-WT, at a much greater extent compared with the negative control 
immunoprecipitated with IgG. Recent findings recognize the displacement of Ezh2 from 
myogenic regulatory regions as a necessary step for the activation of muscle gene 
Fig.9. ChIP analysis of chromatin prepared from RD-WT cells cultured in 
GM with an Ezh2 antibody. The precipitated DNA fragments were 
subjected to real-time PCR analysis using primers designed within MyoG 
and MyH promoters. Fold enrichments are presented as a ratio of the 
amplification efficiency over that of the IgG. Data are shown as an 
average of three independent experiments ± SD. 
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transcription (Aziz et al 2010, Stojic et al., 2011). This data provide further evidence for a 
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4.3. Ezh2 depletion in human RD cells results in a general increase in 
elongating RnaPolII 
The Cdk9/CycT2 complex is a crucial coactivator of myogenesis. The complex coactivates 
MyoD-dependent transcription and its recruitment on myogenic regulatory regions 
correlates with phosphorylation of the CTD of RNApolII (Simone et al., 2002a; Giacinti et 
al., 2006). Our previous results showed that knockdown of Ezh2 determine an increase in 
early and late muscle differentiation markers (Fig.6 and Fig.7). In order to evaluate 
alterations in Cdk9 kinase activity and in RNA processing machinery on gene regulatory 
regions after depletion of Ezh2 we analyzed the CTD phosphorylation state of RNApolII. 
RD-WT and RD-EZH2-KD were cultured in growth medium until reaching confluence. 
Growth medium was then replaced with differentiation medium and total proteins were 
extracted at 0h, 24h, 48h, 72h, 96h after induction of myogenesis. Immunoblot analyses 
were performed against total RNApolII, Ser2P-RnapolII, Ser5P-RNApolII, Ezh2, Cdk9, 
CycT2a-b, and hsp70 and Gapdh as loading controls (Fig. 10).  
Ser2P-RnapolII and Ser5P-RnapolII in RD-EZH2-KD are significantly higher than in RD-WT 
at every time point analyzed. This consent to sustain that there is a general increase in 
the activation of transcription after Ezh2 depletion. The amount of total RNApolII in RD-
WT is similar to the amount in RD-EZH2-KD and these data exclude the possibility that a 
general increase in transcription is due to an augment in RNApolII expression levels. 




         Elena Vittoria Mura “Polycomb protein Ezh2 controls rhabdomyosarcoma formation” 















Fig.10 Immunoblot analyses of MyoG, MyoD, MyhC, Ezh2 from whole cell extracts of human RD-
WT (+) and RD-EZH2-KD (-) at 0h in GM and at 0, 24, 48, 72, 96h in DM. C2C12 murine myoblasts 
at 72h in DM were used as a positive control and equal loading was performed with an anti-Hsp70 
antibody.  
 
It was previously shown by Simone and Giordano (2007) that the signal-dependent 
activation of the Cdk9/CycT2 complex is abrogated in human RD cells. The observed 
increase in the elongating RNApolII confirms that Ezh2 inhibits the transcriptional 
program although it does not impede the normal expression of Cdk9 and CycT2. This puts 
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4.4. Analysis of CTD phosphorylation of RNApolII on Myog and Myh 
promoters 72h after induction of myogenesis 
Upon induction of muscle differentiation, Cdk9 and CycT2 were recruited on regulatory 
regions of myogenin and MyH in myoblasts and this event correlates with 
phosphorylation of the CTD of RnapolII (Simone et al., 2002b; Giacinti et al., 2006). The 
aim of our study was to examine MyoD dependent transcription in Rhabdomyosarcoma 
because it is coactivated by the complex Cdk9/CyCT2 whose activity is abrogated in this 
kind of tumor. To assess how Ezh2 influenced Cdk9 kinase activity we examined the 
occupancy of Ser2P-RNApolII, Ser5P-RNApolII and total RNapolII at Myog and Myh 
promoters. We chose 72h of differentiation as a point to analyze since it was already 
observed that after 72 hours both Myog and MyH proteins were expressed in the 
knockdown RD cell line (Fig.6 and Fig.7). The results demonstrated that fold enrichments 
in Ser2P-RNApolII and Ser5P-RNApolII were higher in RD-EZH2-KD than in RD-WT, with a 
greater occupancy of Ser5P RNApolII (Fig.11 and Fig.11) at both the promoters. These 
data imply a greater activity of the Cdk9/CycT2 complex on the regulatory regions and 
support western blot analyses, which revealed increased Myog and MyH expression in 
RD-EZH2-KD (Fig.7). 
4.5 Cdk9 occupies Myog and Myh promoters in 72h RD-EZH2-KD 
differentiating cells  
To test whether deregulation of muscle-gene expression in RD cells was the result of 
defective enrollment of transcriptional factors, and more in particular to test whether 
Cdk9 recruitment was affected by Ezh2 and to further support the previous experiments 
the same analysis on 72 hours differentiating cells was made with an antibody against 
Cdk9. Interestingly, the ChIP analyses proved that Cdk9 binds Myog and MyH promoters 
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in RD-EZH2-KD but not in RD WT, (Fig.12). This result confirms the hypothesis that the 
activity of Cdk9/CycT2 complex is influenced by the presence of EZH2. 
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Fig.11. ChIP analysis of chromatin prepared from RD-WT cells and RD-
EZH2-KD cells 72h after induction of myogenesis with anti-total RNApolII, 
anti-Ser2P RNApolII, and anti-Ser5P RNapolII. The precipitated DNA 
fragments were subjected to real-time PCR analysis using primers 
designed within MyoG and MyH promoters. Fold enrichments are 
calculated as a ratio of the amplification efficiency over that of the IgG. 
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Fig.12. ChIP of chromatin derived from RD WT and RD-EZH2-KD after 72h in DM with an 
anti-Cdk9 antibody. The precipitated DNA fragments were subjected to real-time PCR 
analysis using primers designed within MyoG and MyH promoters. Fold enrichments are 
normalized to the precipitated DNA folds in RD wild type. Data are shown as an average 
of three independent experiments ± SD. 
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Epigenetic alterations in cancer cells are recognized as an important aspect of tumor 
biology. Unlike genetic alterations, epigenetic modifications can be reversed with specific 
inhibitors or enzymes. Indeed, epigenetically silenced tumor suppressor genes can be 
reactivated to induce apoptosis or senescence. This peculiarity makes epigenetic changes 
an interesting target for therapeutic intervention in cancer. There are at least eight 
distinct types of modifications found on histones: acetylation, methylation, 
phosphorylation, ubiquitylation, sumoylation, ADP ribosylation, deimination, proline 
isomerization (Kouzarides, 2007). In particular specific pattern of acetylation and 
methylation of histones H3 and H4 are associated with several cancer types and for some 
tumors, epigenetic changes enable to distinguish diseases subtype (Fraga et al., 2005; 
Seligson et al., 2005). 
Polycomb group proteins are regulators of embryonic development and stem cell 
maintenance (Pietersen and van Lohuizen; 2008; Kerppola, 2009; Simon and Kingstone, 
2009) and their deregulation contributes to cancer (Sparmann and van Lohuizen 2006; 
Bracken and Helin, 2009). 
Altered expression of Ezh2 has been related to cancer pathogenesis while high Ezh2 
transcript and protein levels have been associated with poor clinical outcome in breast, 
prostate and bladder cancer patients (Varambally et al., 2002; Kleer et al., 2003; Tonini et 
al., 2004). The same protein has been promoted as a diagnostic marker of invasion and 
aggressiveness (Varambally et al., 2002; Raaphorst et al., 2003).  
RMS cells show elevated levels of Ezh2 compared to normal myoblasts. In the early phase 
of myogenesis, this protein maintains repression of muscle specific transcription ensuring 
proper timing in tissue-specific gene expression (Caretti et al., 2004; Stojic et al., 2010). 
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The myogenic transcriptional program is assisted by the complex Cdk9/CycT2, which 
activates MyoD dependent transcription in myoblasts, triggered to differentiate and 
stabilizes the elongating RNApolII on muscle-specific promoters even in synergy with 
other myogenic transcription factors (Simone et al., 2002; Giacinti et al., 2006; Nojima et 
al., 2008). Skeletal differentiation markers are lower in RMS compared to normal 
myoblasts, although the time course of RD-WT induced to differentiate shows that Cdk9 
and CycT2 in RMS are normally expressed (Fig.10). Since Cdk9/CycT2 is a crucial 
coactivator of myogenesis and its activity is abrogated in RD cells (Simone and Giordano, 
2007), these data led us to suppose that Ezh2 could interfere with the kinase activity of 
the complex and to test this hypothesis we compared an RD-WT cell line with an RD-
EZH2-KD cell line. Our results demonstrated that MyoD, myogenin and MyH expressions 
are partially restored after Ezh2 depletion in the RD-Ezh2-KD cell line (Fig.6 and Fig.7). In 
addition ChIP analyses demonstrated the strong occupancy of Ezh2 that is known to 
maintain transcriptional repression of muscle specific genes in the early phase of 
differentiation, at the promoters of Myog and MyH genes in the RD-WT. These data 
suggest that Ezh2 impedes the normal transcriptional regulation in rhabdomyosarcoma. 
The principal activity of the complex Cdk9/CycT2 during myogenesis is the 
phosphorylation of the CTD of RNapolII on myogenic regulatory regions that has been 
already demonstrated for MyoD target genes (Giacinti et al., 2006; Marchesi 2010, 
unpublished results). Overexpression experiments of Cdk9 and CycT2 in the RD cell line 
don’t reestablish the kinase activity of the complex suggesting the possible presence of a 
mechanism inhibiting the complex in rhabdomyosarcoma (Simone and Giordano 2007). 
The extended time course in both RD-WT and RD-EZH2-KD induced to myogenesis allows 
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us to support our assumption. In fact, the RD-EZH2-KD shows an evident increase in both 
RNApolIISer2P and RNApolIISER5P (whose presences indicate active transcription) at 
every time point investigated compared with the RD-WT while the expression levels of 
total RnapolII are comparable between the two cell lines (Fig.10).  
Upon induction of muscle differentiation, Cdk9 and Cyclin T2 were recruited on 
regulatory regions of Myog and MyH in myoblasts and this event correlates with 
phosphorylation of the CTD of RnapolII (Simone et al., 2002b; Giacinti et al., 2006). In RD 
cells Cdk9/CycT2 kinase activity is abrogated. In order to evaluate if the same occurred in 
the RD-EZH2-KD cell line, we analyzed the phosphorylation state of the CTD of RNApolII 
on that genes, because it had been previously shown that Cdk9/CycT2 coactivates 
transcription from these genes. Significantly, ChIP analyses demonstrate that 72h RD-
EZH2-KD differentiating cells exhibit an increase in the phosphorylation state of both Ser2 
and Ser5 of the CTD at Myog and Myh promoters (Fig.9), which agrees with the previous 
results that shows partial reactivation of gene expression (Fig.6 and Fig.7). A greater 
augment is observed in the phosphorylation state of Ser5 at both Myogenin and Myh 
promoters. In addition, further analyses reveal that Ezh2 knockdown restores Cdk9 
occupancy at Myog and Myh promoters in RD-EZH2-KD (Fig.12), with a more evident 
recovery on the myogenin promoter. This is in agreement with the assumption that Ezh2 
interferes with Cdk9 recruitment and activity in rhabdomyosarcoma. In conclusion, our 
results indicate that Ezh2 inhibits transcriptional activation in rhabdomyosarcoma, that 
EZH2 depletion correlates with CTD phosphorylation of RNApolII and interferes with 
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Kinase assays are further needed to completely confirm this hypothesis. If Ezh2 inhibits 
Cdk9 through a direct mechanism or by competing with it is still to be elucidated. The 
comprehension of molecular mechanisms regulating displacement of Ezh2 from myogenic 
regulatory regions will provide further insights on the interplay between Cdk9 and EZh2.  
These studies contribute to a better understanding of the mechanisms triggering the RMS 
carcinogenesis and can be useful in the future to design new therapeutic lines that can be 
combined with other drugs or conventional cancer therapies. 
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